Trial Outcomes & Findings for Informational Nudge to Improve Heart Failure Prescribing (NCT NCT05986695)
NCT ID: NCT05986695
Last Updated: 2026-05-01
Results Overview
The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.
COMPLETED
NA
81 participants
30 days
2026-05-01
Participant Flow
All employed providers within Cardiology and Primary Care units were enrolled into this study per agreement with management.
The leadership of both units agreed that all providers would participate. The 81 participants (providers) were randomly assigned to one of four study arms (control, Alert \[EHR note\], Pier Comparison Report \[Email notification\], or Both \[EHR and Email\]. The providers were numbered and blindly randomize by department, education, and employment site.
Participant milestones
| Measure |
Control
Participants within this arm will not receive any intervention.
|
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note.
|
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Alert & Peer Comparison Report
Participants within this arm would receive the EHR note 2 days prior to an eligible patient and an Email alert every 15 days regarding their ranking concerning the guideline directed medication.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
19
|
19
|
21
|
22
|
|
Overall Study
COMPLETED
|
19
|
19
|
21
|
22
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Informational Nudge to Improve Heart Failure Prescribing
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 30 daysPopulation: The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. The investigators' focus was on increasing the prescription rate. Participants analyzed reflect count of patients.
The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.
Outcome measures
| Measure |
Control
n=10 Participants
Participants within this arm will not receive any intervention.
|
Alert
n=26 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
n=18 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Effectiveness (MRA Prescriptions)
|
0 Count of MRA prescriptions Filled
|
2 Count of MRA prescriptions Filled
|
2 Count of MRA prescriptions Filled
|
2 Count of MRA prescriptions Filled
|
—
|
—
|
PRIMARY outcome
Timeframe: 30 daysPopulation: The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. The investigators' focus was on increasing the prescription rate. Participants analyzed reflect count of patients.
The primary effectiveness outcome is the amount of SGLT2 or MRA prescriptions in eligible HF patients in the three intervention groups compared with the control group within 30 days of appointment. Thirty days is a common time interval for HF outcomes assessment and allows for chart documentation, care coordination, laboratory testing, and medication prescribing that may occur days after a patient encounter. The investigators will record all SGLT2 or MRA prescriptions, including those from non-targeted clinicians, given that nudge interventions, especially the informational alert, may impact other clinicians directly (e.g., view alert in EHR) or indirectly (e.g., referral from targeted clinician). Data represent a cumulative number of prescriptions filled.
Outcome measures
| Measure |
Control
n=55 Participants
Participants within this arm will not receive any intervention.
|
Alert
n=122 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
n=54 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
n=98 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Effectiveness (SGLT2 Prescriptions)
|
2 Count of SGLT2 Prescriptions Filled
|
24 Count of SGLT2 Prescriptions Filled
|
1 Count of SGLT2 Prescriptions Filled
|
16 Count of SGLT2 Prescriptions Filled
|
—
|
—
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: This is the number of clinicians within Primary Care and Cardiology who were participants.
Reach will be measured at the clinician level as the number of unique clinicians who received an informational alert or peer comparison report. The control group did not receive any alert.
Outcome measures
| Measure |
Control
n=19 Participants
Participants within this arm will not receive any intervention.
|
Alert
n=19 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
n=22 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Reach-Clinician
|
0 Participants
|
19 Participants
|
21 Participants
|
22 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: 30 daysPopulation: The deprescribed medicine rate was determined by patient and not associated directly with the participants (clinicians) nor Arms/Groups, being that a patient may be seen by multiple providers.
The investigators will measure safety as the number of patients who were deemed by the participant (clinician) to discontinued prescribed medicine due to suspected adverse effects within 30 days of the nudge interventions.
Outcome measures
| Measure |
Control
n=234 Participants
Participants within this arm will not receive any intervention.
|
Alert
n=151 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
n=169 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
n=234 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
n=151 Participants
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
n=169 Participants
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Incidence of Treatment Emergent Adverse Events
|
3 Deprescribed patients
|
0 Deprescribed patients
|
2 Deprescribed patients
|
1 Deprescribed patients
|
0 Deprescribed patients
|
0 Deprescribed patients
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 14 of the 81 clinicians participated.
Implementation will be assessed by clinician-directed survey of Acceptability of intervention Measure. The REDCap survey was on the Likert Scale: minimum 1 and maximum 5. With 5 being the highest. Acceptability was determine by the number of participants who were neutral or positive with their responses according the the Likert Scale. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.
Outcome measures
| Measure |
Control
n=14 Participants
Participants within this arm will not receive any intervention.
|
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Implementation-Acceptability
Acceptability of the Intervention Measure for the Alert
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Implementation-Acceptability
Acceptability of the Intervention Measure for the Peer Comparison Report
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: The number of patients were not broken down by each participant nor Arm/Group.
At the patient level, Reach will be measured as the number of unique patients for whom the participants received informational alerts
Outcome measures
| Measure |
Control
n=604 Participants
Participants within this arm will not receive any intervention.
|
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Reach-Patient
|
604 Total unique patients
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 6 monthsThe investigators will measure the proportion of alerts relative to the total number of eligible patients with HF; this denominator will allow for comparisons of representativeness of the alert strategy.
Outcome measures
| Measure |
Control
n=19 Participants
Participants within this arm will not receive any intervention.
|
Alert
n=19 Participants
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
n=21 Participants
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
n=22 Participants
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Reach-Comparison of Strategies
|
0 alerts sent
|
211 alerts sent
|
202 alerts sent
|
191 alerts sent
|
—
|
—
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 10 of the 81 clinicians participated.
Appropriateness will be assessed by clinician direct survey of Intervention Appropriateness Measure. Likert scale: minimum 1 and maximum 5. With 5 being the highest. The number of respondents who were neutral and positive were counted. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.
Outcome measures
| Measure |
Control
n=10 Participants
Participants within this arm will not receive any intervention.
|
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Implementation-Appropriateness
Intervention Appropriateness Measure for the Alert
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Implementation-Appropriateness
Intervention Appropriateness Measure for the Peer Comparison Report
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Surveys were anonymous and no identifying information was collected, therefore, investigators are unable to determine which Arm/Group participants with survey responses were assigned. Rows represent responses from the surveys and do not correspond to a specific Arm/Group. The survey was voluntary and only 10 of the 81 clinicians participated.
Feasibility will be assessed by clinician direct survey of Feasibility of Intervention Measure. Likert scale: minimum 1 and maximum 5. With 5 being the highest. The survey participants responded used the Likert scale to determine if the intervention would be feasible. All responses neutral or positive were counted. The anonymous surveys were sent to all in the three groups and did not collect any identifying information.
Outcome measures
| Measure |
Control
n=10 Participants
Participants within this arm will not receive any intervention.
|
Alert
Participants in this arm would be notified 2 days prior of any upcoming appointment with an eligible patient who would benefit from the guideline approved medication via Electronic Health Record Note (Alert).
|
Peer Comparison Report
Participants within this arm received an email alert every 15 days regarding their ranking among their piers in providing the guideline medication administration.
|
Both Alert and Peer Comparison Report
Participants within this arm would receive the Alert (EHR note) 2 days prior to an eligible patient and an Peer Comparison Report (Email alert) every 15 days regarding their ranking concerning the guideline directed medication.
|
Peer Comparison Report (Group 3) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
Alert & Peer Comparison Report (Group 4) MRA Deprescribed
Number of patients that were removed from the guideline directed medication as determined by participants
|
|---|---|---|---|---|---|---|
|
Implementation-Feasibility
Feasibility of the Intervention Measure for the Alert
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Implementation-Feasibility
Feasibility of the Intervention Measure for the Peer Comparison Report
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Peer Comparison Report
Alert & Peer Comparison Report
Control
Alert
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place